$STVN

Santel Luciano sold $41K of STVN

Santel Luciano sold 2,023 shares of Stevanato Group S.p.A. (STVN) at $20.09 on 2026-08-07.

Original reporting
SEC EDGAR · Santel Luciano
Published Aug 10, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$STVN
Neutral
low confidence
Mentioned
$STVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

This provides a new, primary-source datapoint on an insider’s sale activity, but it does not include any new operational, financial, or regulatory information about STVN.

02

Market read

Traders may note the insider sale, but the filing alone is unlikely to change valuation expectations without accompanying company-specific news.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, signal quality is limited.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-10 after-hours; sale dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A. (STVN).

Company-level read

Ticker impact

$STVNNeutralLow confidence
Context

Stevanato Group director Santel Luciano filed a Form 4 open-market sale of 2,023 shares at $20.0900 on 2026-08-07.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, not earnings, guidance, or a corporate event. The article provides sale size and price but no new company-specific fundamentals or catalysts.

Market effects

No clear sector read-through from a single director sale.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as discretionary selling, but the disclosed size is still small relative to typical institutional flows.

Key entities

  • Stevanato Group S.p.A.

    Company whose Form 4 insider sale was disclosed.

  • Santel Luciano

    Director who sold 2,023 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q2 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026 - The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - (PIOMBINO DESE, Italy) – August 4, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.